Breast cancer Clinical Trials in Nashville, TN
As of August 2026, 50 paid clinical trials are recruiting for Breast cancer in Nashville, Tennessee. Compensation typically covers time, travel, and study visits, and many studies also include study-related medical care at no cost.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Related specialties in Nashville
Filter results
50 clinical trials for Breast cancer
·Clear filters·A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer
Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
IKS014 in Advanced Solid Tumors That Express HER2
A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
A Study of Oral MBQ-167 in Participants With Advanced Breast Cancer
A Study of DM001 in Patients With Advanced Solid Tumors
E-Mindfulness Approaches for Living After Breast Cancer
Top Research Study Locations in Nashville
Researchers run research studies in Nashville, TN at 25 active sites. The clinics below currently host the largest number of recruiting studies — each name is followed by the conditions they focus on most.
| Site | Specializes in | Active trials |
|---|---|---|
| Vanderbilt University Medical Center | Colorectal Cancer, Critical Illness, Parkinson Disease | 372 |
| SCRI Oncology Partners | Breast Cancer, Colorectal Cancer, Advanced Solid Tumor | 129 |
| Vanderbilt University/Ingram Cancer Center | Head and Neck Squamous Cell Carcinoma, Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm | 81 |
| Sarah Cannon Research Institute | Advanced Solid Tumor, Advanced Solid Tumors, Colorectal Cancer | 62 |
| Vanderbilt University | Breast Cancer, Cardiac Failure, Graft Rejection | 54 |
| Tennessee Oncology | Multiple Myeloma, Breast Cancer, Carcinoma, Non-Small-Cell Lung | 49 |
| Vanderbilt-Ingram Cancer Center | Breast Cancer, Colorectal Cancer, Endometrial Cancer | 36 |
| The Children's Hospital at TriStar Centennial | Malignant Solid Neoplasm, Acute Myeloid Leukemia, B Acute Lymphoblastic Leukemia | 27 |
| TriStar Centennial Medical Center | Coronary Artery Disease, Acute Lower Limb Arterial Occlusion, Acute Myeloid Leukemia (AML) | 16 |
| Tennessee Oncology, PLLC | Advanced Solid Tumor, Breast Cancer, Advanced Breast Cancer | 13 |
| Vanderbilt Breast Center at One Hundred Oaks | Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Malignant Solid Neoplasm, Advanced Malignant Solid Neoplasm | 13 |
| Monroe Carell Jr. Children's Hospital at Vanderbilt | Acute Kidney Injury, Acute Myeloid Leukemia, Angelman Syndrome | 12 |
| Tennessee Valley Healthcare System Nashville Campus, Nashville, TN | Cardiovascular Disease, Acute Kidney Injury (AKI), Aging | 10 |
| Ascension Saint Thomas | Coronary Artery Disease, Mitral Regurgitation, Acute or Chronic Coronary Artery Disease | 9 |
| GSK Investigational Site | Neoplasms, Multiple Myeloma, Irritable Bowel Syndrome | 9 |
| Sarah Cannon Research Institute Oncology Partners | Advanced Solid Tumors, Advanced Cancer, Advanced NRAS-Mutant Melanoma | 9 |
| Henry-Joyce Cancer Clinic | Colorectal Neoplasms, Breast Cancer, Colonic Diseases | 8 |
| Tennessee Retina, PC | Geographic Atrophy, Neovascular Age-Related Macular Degeneration (nAMD), Age-related Macular Degeneration (AMD) | 8 |
| Vanderbilt Eye Institute | Geographic Atrophy (GA), Macular Edema Secondary to Inflammation, Age - Related Macular Degeneration (AMD) | 8 |
| Centennial Medical Center | Cardiovascular Diseases, Coronary Artery Disease, Heart Failure | 7 |
| Vanderbilt Medical Center | Acinar Cell Carcinoma, Advanced Cancer, Alzheimer Disease | 7 |
| Autonomic Dysfunction Center/ Vanderbilt University Medical Center | Autonomic Failure, Multiple System Atrophy, Pure Autonomic Failure | 6 |
| Meharry Medical College | ARDS, Cardiovascular Diseases, Cognitive Impairment, Mild | 6 |
| Sarah Cannon Research Institute (SCRI) Oncology Partners | Advanced Solid Tumor, Metastatic Solid Tumor, Ovarian Cancer | 6 |
| Sarah Cannon Research Institute - Pharmacy | Gastroesophageal Junction Adenocarcinoma, Advanced Cancer, Advanced Colorectal Cancer (Part 1) | 6 |
Active & Upcoming Studies in Nashville (2026)
Recruiting trials in Nashville grouped by therapeutic area, drawn from ClinicalTrials.gov. Each bucket shows the most recent example studies.
Cancer & tumors (561 active studies)
- Pilot Study of Casdatifan-Treated Refractory Renal Cell Carcinoma · EARLY_Phase 1 · Vanderbilt-Ingram Cancer Center
- A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma · Phase 3 · AbbVie
Cardiovascular (90 active studies)
- Cor360: Clinician-Facing Broad-Spectrum Cardiac Phenotyping and Risk Assessment Using COR® Wearable ECG to Inform Outcomes-Oriented Care Pathways · Peerbridge Health, Inc
- A Study of VARIPULSE Catheter in Participants With Persistent Atrial Fibrillation Undergoing Pulmonary Vein and Superior Vena Cava Isolation · Biosense Webster, Inc.
Neurology & pain (61 active studies)
- The Impact of Perioperative Lidocaine Infusions on Enhanced Recovery After Non-Cardiac Surgery · Phase 4 · Vanderbilt University Medical Center
- 2-Hydroxybenzylamine (2-HOBA) Study in Early Alzheimer's Patients · Phase 1, Phase 2 · MTI Biotech Inc
Diabetes & metabolic (50 active studies)
- HMB Plus Vitamin D to Preserve Muscle in Older Adults Starting Semaglutide · Phase 2 · Vanderbilt University Medical Center
- Transition to Ambulatory Bariatric Surgery (TABS) Trial · Vanderbilt University Medical Center
Eye & vision (21 active studies)
- A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration · Phase 3 · Amgen
- A Study in People With Diabetic Macular Edema to Test How Well Different Doses of BI 3812465 Are Tolerated · Phase 1, Phase 2 · Boehringer Ingelheim
Mental health & behavior (16 active studies)
- Cognitive Enhancement in Recurrent Depression (The COG-D-R Study) · Vanderbilt University Medical Center
- GLP-1 Receptor Agonists to Decrease Ethanol and CVD Risk in HIV · Phase 2 · Vanderbilt University Medical Center
Vaccines (8 active studies)
- A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Given to Healthy Children 4 to 6 Years of Age · Phase 3 · GlaxoSmithKline
- Effect of 2-HOBA in Persistent Immune Activation in Long COVID POTS · Phase 2 · Vanderbilt University Medical Center
HIV / STI (7 active studies)
- Phase 1 Study of CH505 HIV Vaccine Nanoparticles and mRNA Boosters in Healthy Adults · Phase 1 · National Institute of Allergy and Infectious Diseases (NIAID)
- GLP-1 Receptor Agonists to Decrease Ethanol and CVD Risk in HIV · Phase 2 · Vanderbilt University Medical Center
Pediatric (7 active studies)
- Neonatal Platelet Transfusion Threshold Trial · NICHD Neonatal Research Network
- Safety Study to Evaluate the Occurrence of EFAD in Pediatric Patients With PNAC Who Require More Than Eight Weeks of Omegaven Treatment · Fresenius Kabi
Common conditions studied in Nashville
- Breast Cancer (43 active studies)
- Colorectal Cancer (32 active studies)
- Advanced Solid Tumor (30 active studies)
- Ovarian Cancer (28 active studies)
- Multiple Myeloma (24 active studies)
- Prostate Cancer (24 active studies)
Leading research sponsors in Nashville
- Vanderbilt University Medical Center
- AstraZeneca
- Vanderbilt-Ingram Cancer Center
- National Cancer Institute (NCI)
- Merck Sharp & Dohme LLC
Frequently asked questions
How many paid clinical trials are currently recruiting in Nashville?
There are approximately 1,355 recruiting clinical trials in Nashville, Tennessee listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in Nashville pay participants?
Most recruiting trials in Nashville compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in Nashville?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in Nashville?
The most common conditions under active study in Nashville include Breast Cancer (43), Colorectal Cancer (32), Advanced Solid Tumor (30), Ovarian Cancer (28), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in Nashville?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in Nashville on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in Nashville?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in Nashville?
Recruiting research sites in Nashville include Vanderbilt University Medical Center, SCRI Oncology Partners, Vanderbilt University/Ingram Cancer Center, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in Nashville right now?
The largest active categories in Nashville are Cancer & tumors (561), Cardiovascular (90), Neurology & pain (61). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.